Proliferation inhibition and the underlying molecular mechanisms of microRNA‑30d in renal carcinoma cells

Yu,Hongsheng; Lin,Xialu; Wang,Fang; Zhang,Burong; Wang,Weihua; Shi,Hongbo; Zou,Baobo; Zhao,Jinshun

doi:10.3892/ol.2013.1754

Proliferation inhibition and the underlying molecular mechanisms of microRNA‑30d in renal carcinoma cells

Authors:
- Hongsheng Yu
- Xialu Lin
- Fang Wang
- Burong Zhang
- Weihua Wang
- Hongbo Shi
- Baobo Zou
- Jinshun Zhao
View Affiliations

Affiliations: Medical School, Ningbo University, Zhejiang Provincial Key Laboratory of Pathological and Physiological Technology, Ningbo, Zhejiang 315211, P.R. China, Affiliated Hospital, Ningbo University, Zhejiang Provincial Key Laboratory of Pathological and Physiological Technology, Ningbo, Zhejiang 315211, P.R. China
Published online on: December 11, 2013 https://doi.org/10.3892/ol.2013.1754
Pages: 799-804

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To investigate the inhibitory effects of microRNA‑30d (miR‑30d) on renal carcinoma cell proliferation and the underlying molecular mechanisms, miR‑30d expression in renal cell carcinoma (RCC) specimens was analyzed by quantitative polymerase chain reaction (qPCR). The inhibition of the proliferation of miR‑30d on renal carcinoma cells (ACHN cell line) was analyzed by MTT and colony formation assays. The effects of miR‑30d on cyclin E2 expression were detected by the luciferase activity of the reporter gene. In addition, the effects of miR‑30d on endogenous cyclin E2 expression at the RNA and protein levels were investigated by qPCR and western blot analysis, respectively. Cell cycles were analyzed by flow cytometry. The results showed the following: i) Expression of miR‑30d was significantly downregulated in renal carcinoma tissues compared with paraneoplastic tissues; ii) overexpression of miR‑30d inhibited renal carcinoma cell proliferation and colony formation; iii) miR‑30d inhibited cyclin E2 3' untranslated region‑mediated reporter gene expression; and iv) overexpression of miR‑30d downregulated endogenous cyclin E2 expression and blocked the cell cycle at the G1 phase. In conclusion, miR‑30d functions as a tumor suppressor gene in RCC and inhibits renal carcinoma cell proliferation. Cell cycle regulatory factor cyclin E2 is a target gene of miR‑30d. miR‑30d inhibits renal carcinoma cell proliferation via the regulation of cyclin E2 expression at the post‑transcriptional level.

View Figures

View References

1	Farber LJ, Furge K and Teh BT: Renal cell carcinoma deep sequencing: recent developments. Curr Oncol Rep. 14:240–248. 2012. View Article : Google Scholar : PubMed/NCBI
2	Reuter VE: The pathology of renal epithelial neoplasms. Semin Oncol. 33:534–543. 2006. View Article : Google Scholar : PubMed/NCBI
3	Itsumi M and Tatsugami K: Immunotherapy for renal cell carcinoma. Clin Dev Immunol. 2010:2845812010. View Article : Google Scholar : PubMed/NCBI
4	Walsh N, Larkin A, Kennedy S, et al: Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol. 9:62009. View Article : Google Scholar : PubMed/NCBI
5	Linehan WM, Rubin JS and Bottaro DP: VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. Int J Biochem Cell Biol. 41:753–756. 2009. View Article : Google Scholar : PubMed/NCBI
6	Linehan WM, Pinto PA, Srinivasan R, et al: Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res. 13:671s–679s. 2007. View Article : Google Scholar : PubMed/NCBI
7	An J and Rettig MB: Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity. Mol Cell Biol. 25:7546–7556. 2005. View Article : Google Scholar : PubMed/NCBI
8	Peruzzi B, Athauda G and Bottaro DP: The von Hippel-Lindau tumor suppressor gene product represses oncogenic β-catenin signaling in renal carcinoma cells. Proc Natl Acad Sci USA. 103:14531–14536. 2006.PubMed/NCBI
9	Conrad PW, Freeman TL, Beitner-Johnson D and Millhorn DE: EPAS1 trans-activation during hypoxia requires p42/p44 MAPK. J Biol Chem. 274:33709–33713. 1999. View Article : Google Scholar : PubMed/NCBI
10	Carrington JC and Ambros V: Role of microRNAs in plant and animal development. Science. 301:3362003. View Article : Google Scholar : PubMed/NCBI
11	Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
12	Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
13	Horikawa Y, Wood CG, Yang H, et al: Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res. 14:7956–7962. 2008. View Article : Google Scholar : PubMed/NCBI
14	Trang P, Weidhaas J and Slack F: MicroRNAs as potential cancer therapeutics. Oncogene. 27(Suppl 2): S52–S57. 2008. View Article : Google Scholar
15	Didiano D and Hobert O: Perfect seed pairing is not a generally reliable predictor for miRNA-target interactions. Nat Struct Mol Biol. 13:849–851. 2006. View Article : Google Scholar
16	Yao J, Liang L, Huang S, et al: MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. Hepatology. 51:846–856. 2010.PubMed/NCBI
17	Hand NJ, Master ZR, Eauclaire SF, Weinblatt DE, Matthews RP and Friedman JR: The microRNA-30 family is required for vertebrate hepatobiliary development. Gastroenterology. 136:1081–1090. 2009. View Article : Google Scholar : PubMed/NCBI
18	Bruchova H, Merkerova M and Prchal JT: Aberrant expression of microRNA in polycythemia vera. Haematologica. 93:1009–1016. 2008. View Article : Google Scholar : PubMed/NCBI
19	Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
20	Schlaeger C, Longerich T, Schiller C, et al: Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology. 47:511–520. 2008. View Article : Google Scholar
21	Tang X, Muniappan L, Tang G and Ozcan S: Identification of glucose-regulated miRNAs from pancreatic (beta) cells reveals a role for miR-30d in insulin transcription. RNA. 15:287–293. 2009. View Article : Google Scholar
22	Marton S, Garcia MR, Robello C, et al: Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia. 22:330–338. 2008. View Article : Google Scholar : PubMed/NCBI
23	Visone R, Pallante P, Vecchione A, et al: Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene. 26:7590–7595. 2007. View Article : Google Scholar : PubMed/NCBI
24	Wu C, Jin B, Chen L, et al: MiR-30d induces apoptosis and is regulated by the Akt/FOXO pathway in renal cell carcinoma. Cell Signal. 25:1212–1221. 2013. View Article : Google Scholar : PubMed/NCBI
25	Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ and Teh BT: MicroRNA profiling of human kidney cancer subtypes. Int J Oncol. 35:109–114. 2009. View Article : Google Scholar : PubMed/NCBI
26	Nakada C, Matsuura K, Tsukamoto Y, et al: Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol. 216:418–427. 2008. View Article : Google Scholar : PubMed/NCBI
27	Juan D, Alexe G, Antes T, et al: Identification of a microRNA panel for clear-cell kidney cancer. Urology. 75:835–841. 2010. View Article : Google Scholar : PubMed/NCBI
28	Pantuck AJ, Seligson DB, Klatte T, et al: Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer. 109:2257–2267. 2007. View Article : Google Scholar : PubMed/NCBI
29	Rathmell WK and Chen S: VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Rev Anticancer Ther. 8:63–73. 2008. View Article : Google Scholar : PubMed/NCBI
30	Redova M, Svoboda M and Slaby O: MicroRNAs and their target gene networks in renal cell carcinoma. Biochem Biophys Res Commun. 405:153–156. 2011. View Article : Google Scholar : PubMed/NCBI
31	Esposito F, Tornincasa M, Pallante P, et al: Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J Clin Endocrinol Metab. 97:E710–E718. 2012. View Article : Google Scholar : PubMed/NCBI
32	Chen LZ, Niu XH, Han XL, Xie BS and Mao ZB: Down-regulation of miR-30d on proliferation of HeLa cells. Chinese Journal of Biochemistry and Molecular Biology. 11:1047–1052. 2009.
33	Kumar M, Lu Z, Takwi AA, et al: Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene. 30:843–853. 2010. View Article : Google Scholar : PubMed/NCBI
34	Lu Y, Ryan SL, Elliott DJ, et al: Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22–q24.23 in medulloblastoma. PLoS One. 4:e61592009.PubMed/NCBI